Literature DB >> 10997836

Factors determining the use of hormone replacement therapy in recent naturally postmenopausal women participating in the French SU.VI.MAX cohort.

S Mohammed-Cherif1, S Briançon, G Potier de Courcy, P Preziosi, B Fieux, M Zarebska, P Galan, S Hercberg.   

Abstract

The determinants of hormone replacement therapy (HRT) were studied in a cohort of recently postmenopausal women participating, in France, in a nutritional study (SU.VI.MAX Study). Analysis was performed-analysis on 592 women aged 45 years or more, who had undergone natural menopause which appeared in the 2 previous years. No differences were observed in education level, socio-professional categories, marital status, geographic residence, smoking habits, physical activity, or past contraceptive practice. Past regular gynecologic follow-up appeared to be the strongest determinant of HRT use (odds ratio [OR]: 3.18). Women who reported having had at least one of the studied pathologies (past history of breast cancer, phlebitis, anger, uterine fibroma, hypertension, diabetes or hypercholesterolemia), past abundant menstrual blood losses, and with body mass index (BMI) > or = 25 were less likely to be taking HRT than women free of pathology, with no history of past abundant menstrual blood losses and with low BMI (OR respectively of 0.40, 0.64, 0.62). Women over 51.3 years of age were less likely to use HRT than younger women (OR: 0.92). Finally, in our population, while socio-economic level was not a major determinant of HRT use, the regularity of gynecological follow-up before menopause, overweight, and the existence of a definite or possible contra-indication were strong determinants of HRT use.

Entities:  

Mesh:

Year:  2000        PMID: 10997836     DOI: 10.1023/a:1007616029063

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN: 0393-2990            Impact factor:   8.082


  24 in total

1.  Postmenopausal estrogen use, cigarette smoking, and cardiovascular morbidity in women over 50. The Framingham Study.

Authors:  P W Wilson; R J Garrison; W P Castelli
Journal:  N Engl J Med       Date:  1985-10-24       Impact factor: 91.245

2.  Postmenopausal estrogen use and mortality. Results from a prospective study in a defined, homogeneous community.

Authors:  M H Criqui; L Suarez; E Barrett-Connor; J McPhillips; D L Wingard; C Garland
Journal:  Am J Epidemiol       Date:  1988-09       Impact factor: 4.897

3.  Characteristics of noncontraceptive hormone users.

Authors:  G M Egeland; K A Matthews; L H Kuller; S F Kelsey
Journal:  Prev Med       Date:  1988-07       Impact factor: 4.018

4.  A case-control study of myocardial infarction in relation to use of estrogen supplements.

Authors:  L Rosenberg; J R Palmer; S Shapiro
Journal:  Am J Epidemiol       Date:  1993-01-01       Impact factor: 4.897

5.  Use of postmenopausal hormone replacement therapy: estimates from a nationally representative cohort study.

Authors:  K M Brett; J H Madans
Journal:  Am J Epidemiol       Date:  1997-03-15       Impact factor: 4.897

6.  Determinants of hormone replacement therapy among postmenopausal women enrolled in the French GAZEL cohort.

Authors:  V Ringa; B Ledésert; G Bréart
Journal:  Osteoporos Int       Date:  1994-01       Impact factor: 4.507

7.  Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. The Atherosclerosis Risk in Communities Study Investigators.

Authors:  A A Nabulsi; A R Folsom; A White; W Patsch; G Heiss; K K Wu; M Szklo
Journal:  N Engl J Med       Date:  1993-04-15       Impact factor: 91.245

8.  Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study.

Authors:  M J Stampfer; G A Colditz; W C Willett; J E Manson; B Rosner; F E Speizer; C H Hennekens
Journal:  N Engl J Med       Date:  1991-09-12       Impact factor: 91.245

9.  Determinants of hormonal replacement therapy in recently postmenopausal women.

Authors:  V Ringa; B Ledésert; R Gueguen; F Schiele; G Breart
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  1992-07-24       Impact factor: 2.435

10.  Compliance with hormone therapy.

Authors:  V A Ravnikar
Journal:  Am J Obstet Gynecol       Date:  1987-05       Impact factor: 8.661

View more
  1 in total

Review 1.  Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases.

Authors:  Goran Bjelakovic; Dimitrinka Nikolova; Lise Lotte Gluud; Rosa G Simonetti; Christian Gluud
Journal:  Cochrane Database Syst Rev       Date:  2012-03-14
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.